- Home
- MUFG vs MRK Comparison
MUFG vs MRK Comparison
Compare MUFG & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | MRK |
|---|---|---|
| Founded | 1880 | 2000 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.9B | 317.8B |
| IPO Year | 2002 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MUFG | MRK |
|---|---|---|
| Price | $23.49 | $148.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $125.59 |
| AVG Volume (30 Days) | 2.7M | ★ 5.5M |
| Earning Date | 05-15-2026 | 04-30-2026 |
| Dividend Yield | 2.32% | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $4.62 | $3.61 |
| Revenue Next Year | $10.12 | $5.41 |
| P/E Ratio | $25.47 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $14.65 | $78.03 |
| 52 Week High | $24.26 | $157.00 |
Technical Indicators
Market Signals| Indicator | MUFG | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 56.54 |
| Support Level | $21.50 | $145.75 |
| Resistance Level | $24.26 | $152.80 |
| Average True Range (ATR) | 0.33 | 3.14 |
| MACD | -0.10 | -0.44 |
| Stochastic Oscillator | 70.60 | 56.04 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).